How do Pharma, Biotech, MedTech and IVD manufacturers manage supply shortages proactively, before they turn into a supply gap and a reportable event?

In a regulated environment, supply shortages rarely emerge suddenly, but they become visible too late. The real trigger is not the missing quantity but the missing lead time: once stock starts running down, the sequence of countermeasures is already lost.

In Life Sciences, an alternative source cannot be switched in at short notice, because it must be qualified before the first delivery.

Proactive shortage management therefore starts with the criticality analysis: which materials depend on a single source, how long is their lead time, and how demanding would a switchover be.

Only this list determines where a second source should be qualified in advance, where differentiated safety stock should be held, and where blanket stock with limited shelf life merely ties up capital and generates write-offs.

The second logic is that of the reporting obligation. In regulated industries a shortage is not an internal problem but a matter with statutorily defined recipients and deadlines.

For medicinal products, the reporting obligations under § 52b AMG and the framework of Regulation (EU) 2022/123 apply, with monitoring via the European Shortages Monitoring Platform; for medical devices and IVDs, Art. 10a of the MDR (EU) 2017/745 and the IVDR (EU) 2017/746 requires advance information to downstream actors, healthcare institutions and the competent authority.

Setting up the reporting process only during a crisis produces a second finding alongside the shortage itself. The reporting process therefore belongs defined in advance and connected to risk management, so that allocation is documented, the root cause is addressed, and recurrence becomes less likely.